Infra-low frequency neurofeedback training (ILF-NFT) could become part of the treatment regimen for Dravet syndrome (DS), according to a study recently published in Epilepsy & Behavior Reports. “We highlight the beneficial effects on symptom reduction in seizure frequency and severity, as well as significantly improved sleep quality, including improvements in cognition, learning, and motor functioning,…
Primary caregivers of patients with Dravet syndrome (DS) experience decreased sleep quality which correlated with increased levels of depression and anxiety, according to a study published in the Orphanet Journal of Rare Diseases. The mean Pittsburgh Sleep Quality Index (PSQI) score was 8.7 ± 3.5 for the overall group of German caregivers surveyed in the study.…
Soticlestat is associated with sustained seizure reductions in patients with Lennox-Gastaut syndrome and Dravet syndrome, according to interim data from an ongoing phase 2 clinical trial presented at the American Academy of Neurology’s (AAN) 75th Annual Meeting between April 22 and 27 in Denver, Colorado. Safety findings from the interim analysis were consistent with previous…
Patients with Lennox–Gastaut syndrome receiving soticlestat as adjunctive therapy had reduced median frequency in specific types of seizures according to a post hoc analysis of results from a clinical trial called Elektra, which were presented at the American Academy of Neurology’s (AAN) 75th Annual Meeting held in Denver, Colorado, between April 22 and 27, 2023.…
The use of pharmaceutical cannabidiol (CBD) in Lennox-Gastaut syndrome and Dravet syndrome is beneficial both in terms of seizure reduction and improvements in patients’ quality of life, according to a new Italian study published in the journal Expert Opinion on Pharmacotherapy. However, the authors warned that more research is necessary to confirm the effects of…
Please login or register first to view this content.
